Last updated: 2026-09-06 23:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Oculis Holding AG (OCS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $12,18, with a market capitalisation of $667,45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10,52 to $34,48. This page covers its latest market performance, valuation, price trends and company information.
$667,45M | |
$12,07 | |
$34,48 | |
$6,26 | |
$12,17 | |
108,91K | |
-- | |
-- | |
$34,48 | |
$10,52 | |
-- | |
-- |
Oculis Holding AG (OCS) last closed at $12,17 as of 2026-09-04 23:31:00, unchanged from the previous close of $12,17.
During the latest regular trading session, OCS traded between $6,26 and $34,48, with a volume of 108,91K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Oculis Holding AG (OCS) moved from $12,11 to $12,18, representing a gain of 0,61% ($0,07).
The stock traded between $11,98 and $12,39 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 145,34 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6,9%
OCS is currently trading at $12,18, placing it 6,9% of the way from its 52-week low of $10,52 to its 52-week high of $34,48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
| Employees | 60 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Oculis Holding AG (OCS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.